MedTrace Logo

Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis

NCT03132623 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2017-05-01

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 4 clinical trial to evaluate the efficacy and safety of andrographolide sulfonate in patients with acute bronchitis

Conditions

  • Acute Bronchitis

Interventions

DRUG

andrographolide sulfonate

Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.

DRUG

andrographolide sulfonate simulation

Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.

Sponsors & Collaborators

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Wei Zhang · The First Affiliated Hospital of Nanchang University

  • Ping Xu · The Fourth Affiliated Hospital of Nanchang University

  • Weiyou Liu · First Affiliated Hospital of Gannan Medical University

  • Jun Li · Jiujiang First People's Hospital

  • Xianghua Zhang · First Hospital of Shijiazhuang City

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2017-12-30
Completion
2018-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03132623 on ClinicalTrials.gov